Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1108693

	registered interest
	date	01/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on the prescription of medicinal cannabis oil for patients with (a) cerebral palsy and (b) arthritis.
	tabling member constituency	Banff and Buchan
	tabling member printed	David Duguid
	uin	239283
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>The Department has not discussed with the National Institute for Health and Care Excellence (NICE) the prescription of medicinal cannabis oil for patients with cerebral palsy and arthritis.</p><p> </p><p>NICE is the independent expert body that develops authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE is developing guidance on the prescribing of cannabis-based medicinal products by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p><p> </p><p>Following a public consultation on the draft scope, the guidance will focus on the use of cannabis-based products in the treatment of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy, conditions where the evidence is currently most advanced. A consultation on the draft guidance is expected in the summer.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 09/04/2019 14:41:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4606 label Biography information for David Duguid

1109066

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the survival rate of patients with pancreatic cancer.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	239856
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>Later this year, the Government will begin the roll-out of new Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise, which focus on diagnosing cancers where patients often present with non-specific symptoms, like pancreatic cancer, and may go to their general practitioner (GP) many times before being sent for tests.</p><p> </p><p>This is part of the NHS Long Term Plan that was published in January 2019. It sets a new ambition that, by 2028, the proportion of cancers diagnosed at stages 1 and 2 will rise from around half now to three-quarters of cancer patients. Achieving this will mean that, from 2028, 55,000 more people each year will survive their cancer for at least five years after diagnosis. We will build on work to raise greater awareness of symptoms of cancer, lower the threshold for referral by GPs, accelerate access to diagnosis and treatment and maximise the number of cancers that we identify through screening. This includes the use of personalised and risk stratified screening and beginning to test the family members of cancer patients where they are at increased risk of cancer.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/04/2019 15:28:26 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1109073

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hyperkalaemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the prevalence of hyperkalaemia for patients with chronic kidney disease.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	239857
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>Hyperkalaemia usually occurs in patients with renal impairment which can be acute or chronic. In patients with chronic kidney disease (CKD), several factors increase susceptibility to hyperkalaemia including a high dietary potassium intake relative to residual renal function. When patients with CKD have other risk factors, for example treatment with drugs that interfere with the renin-angiotensin-aldosterone system, the risk of hyperkalaemia is further increased. Clinical presentation of hyperkalaemia is highly variable with some patients presenting with an acute illness whilst others may be asymptomatic.</p><p> </p><p>Although not completely preventable, the risk of developing hyperkalaemia can be reduced. Clinical practice guidelines treatment of acute hyperkalaemia in adults, a collaboration between the Renal Association and Resuscitation Council UK that is endorsed by a range of organisations, including the College of Emergency Medicine and the Faculty of Intensive Care medicine, sets out evidence-based guidance on the management of the condition. It was developed to improve the treatment of acute hyperkalaemia and to reduce the risk of complications associated with hyperkalaemia and its treatment. The main measures in primary prevention in patients with CKD are regular blood monitoring, careful drug prescribing and dietary advice. Patient information and education may reduce the risk of inadvertent hyperkalaemia. The guidance can be found at the following link:</p><p> </p><p><a href="https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf" target="_blank">https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf</a></p><p> </p><p>Information regarding the annual cost to the National Health Service of treating hyperkalaemia in Coventry South and England is not available. This answer covers England only. Funding of such services in the other United Kingdom nations is a matter for the respective devolved administrations.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239865 question first answered 08/04/2019 15:20:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1109260

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hyperkalaemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the annual cost to the NHS of treating hyperkalaemia in (a) Coventry South constituency and (b) the UK.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	239865
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>Hyperkalaemia usually occurs in patients with renal impairment which can be acute or chronic. In patients with chronic kidney disease (CKD), several factors increase susceptibility to hyperkalaemia including a high dietary potassium intake relative to residual renal function. When patients with CKD have other risk factors, for example treatment with drugs that interfere with the renin-angiotensin-aldosterone system, the risk of hyperkalaemia is further increased. Clinical presentation of hyperkalaemia is highly variable with some patients presenting with an acute illness whilst others may be asymptomatic.</p><p> </p><p>Although not completely preventable, the risk of developing hyperkalaemia can be reduced. Clinical practice guidelines treatment of acute hyperkalaemia in adults, a collaboration between the Renal Association and Resuscitation Council UK that is endorsed by a range of organisations, including the College of Emergency Medicine and the Faculty of Intensive Care medicine, sets out evidence-based guidance on the management of the condition. It was developed to improve the treatment of acute hyperkalaemia and to reduce the risk of complications associated with hyperkalaemia and its treatment. The main measures in primary prevention in patients with CKD are regular blood monitoring, careful drug prescribing and dietary advice. Patient information and education may reduce the risk of inadvertent hyperkalaemia. The guidance can be found at the following link:</p><p> </p><p><a href="https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf" target="_blank">https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf</a></p><p> </p><p>Information regarding the annual cost to the National Health Service of treating hyperkalaemia in Coventry South and England is not available. This answer covers England only. Funding of such services in the other United Kingdom nations is a matter for the respective devolved administrations.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239857 question first answered 08/04/2019 15:20:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1109188

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Bexley
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the average waiting time for patients to see their GP in Bexley has been for (a) non-emergency appointments and (b) emergency appointments in the last twelve months.
	tabling member constituency	Bexleyheath and Crayford
	tabling member printed	Sir David Evennett
	uin	239895
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>Bexley Clinical Commissioning Group (CCG) currently only captures data from four of its 23 general practices due to interoperability issues with one of the clinical system suppliers. However, national roll out of a new system to share this data is expected this month, meaning the relevant data for the remaining practices in Bexley should be available from May 2019.</p><p> </p><p>The time between booking an appointment with a general practice and having the appointment, in days, for the practices where data is currently collected in Bexley CCG is presented in the attached table for the last available published date which was February 2019. A 12 month average from March 2018 - February 2019 has also been presented along with a comparison to the average across all appointments in England. NHS Digital’s ‘Appointments in General Practice’ data is published monthly with a two-month time lag.</p><p> </p><p>The appointments data does not differentiate between emergency and routine appointments in general practice and the ‘time from booking to appointment’ does not take into consideration that many patients will be appropriately booking ahead as part of the continuity of care they receive for long-term conditions.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Bexley</p></td><td><p>England</p></td><td><p>Bexley</p></td><td><p>England</p></td></tr><tr><td><p> </p></td><td colspan="2"><p>February 2019</p></td><td colspan="2"><p>March 2018 to February 2019</p></td></tr><tr><td><p>Same Day</p></td><td><p>35.8%</p></td><td><p>42.3%</p></td><td><p>38.1%</p></td><td><p>42.2%</p></td></tr><tr><td><p>1 Day</p></td><td><p>6.2%</p></td><td><p>6.8%</p></td><td><p>6.8%</p></td><td><p>6.8%</p></td></tr><tr><td><p>2 to 7 Days</p></td><td><p>20.6%</p></td><td><p>19.8%</p></td><td><p>22.9%</p></td><td><p>20.1%</p></td></tr><tr><td><p>8 to 14 Days</p></td><td><p>20.1%</p></td><td><p>14.4%</p></td><td><p>17.2%</p></td><td><p>13.8%</p></td></tr><tr><td><p>15 to 21 Days</p></td><td><p>8.5%</p></td><td><p>7.6%</p></td><td><p>7.4%</p></td><td><p>7.4%</p></td></tr><tr><td><p>22 to 28 Days</p></td><td><p>5.8%</p></td><td><p>5.1%</p></td><td><p>4.7%</p></td><td><p>5.0%</p></td></tr><tr><td><p>More than 28 Days</p></td><td><p>2.9%</p></td><td><p>4.0%</p></td><td><p>3.0%</p></td><td><p>4.7%</p></td></tr><tr><td><p>Total</p></td><td><p>100.0%</p></td><td><p>100.0%</p></td><td><p>100.0%</p></td><td><p>100.0%</p></td></tr></tbody></table><p> </p><p>The time between booking an appointment with a general practice and having the appointment, in days, for all data available in Bexley CCG is presented above for the last published month February 2019 and as a 12 month average from March 2018 - February 2019 along with a comparison to the average across all appointments in England.</p><p>Notes:</p><ol><li>Data has only been able to be captured from up to four out of the 23 GP practices in Bexley due to interoperability issues with one of the clinical system suppliers.</li><li>NHS Digital currently only publish data from Egton Medical Information Systems (EMIS) and The Phoenix Partnership (TPP) practice systems but are working with other general practitioner (GP) systems to bring them on board in future developments.</li><li>There are several factors that drive the time from a booking to an appointment. This includes appointment availability at the practice, patient availability, the urgency of the appointment and GP advice.</li><li>The data does not differentiate between emergency and routine appointments in general practice.</li><li>The data does not include any information about the patients or clinical information.</li><li>The data in the response includes appointments with all healthcare professional types, including GPs and other practice staff.</li><li>Not all practices in England are included in the appointments in general practice publication, meaning the total number of appointments is not known.</li><li>Same day and next day bookings are of particular interest so are presented here separately. Further bookings are presented grouped by weeks.</li><li>The number of appointments that have already happened is provided as recorded in participating EMIS and TPP practices in England. The data presented only contains information which was captured on the GP practice systems. This limits the activity reported on and does not represent all work happening within a primary care setting.</li></ol><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/04/2019 13:34:29 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1198 label Biography information for Sir David Evennett

1109124

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dermatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps are being taken by (a) his Department, (b) NHS England and (c) NICE to ensure there is a NICE clinical guideline and quality standard in place for atopic dermatitis in adults.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	239946
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>NHS England is the principal commissioner of clinical guidelines and National Health Service related quality standards from the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>NICE and NHS England have been in discussion about developing a clinical guideline and quality standard on atopic dermatitis (eczema) in adults. NHS England has recently consulted on a draft policy which included the prescribing of emollient bath and shower preparations for dry and pruritic skin conditions and will consider the appropriateness of referring a guideline on atopic dermatitis in adults to NICE after the consultation responses have been reviewed.</p><p> </p><p>Details of this can be seen in the consultation document at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed-update/user_uploads/low-priority-prescribing-consultation-guidance.pdf" target="_blank">https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed-update/user_uploads/low-priority-prescribing-consultation-guidance.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239947 question first answered 10/04/2019 13:28:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4056 label Biography information for Nic Dakin

1109125

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dermatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department supports the prioritisation of atopic dermatitis in adults as a topic for guideline development by NICE.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	239947
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>NHS England is the principal commissioner of clinical guidelines and National Health Service related quality standards from the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>NICE and NHS England have been in discussion about developing a clinical guideline and quality standard on atopic dermatitis (eczema) in adults. NHS England has recently consulted on a draft policy which included the prescribing of emollient bath and shower preparations for dry and pruritic skin conditions and will consider the appropriateness of referring a guideline on atopic dermatitis in adults to NICE after the consultation responses have been reviewed.</p><p> </p><p>Details of this can be seen in the consultation document at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed-update/user_uploads/low-priority-prescribing-consultation-guidance.pdf" target="_blank">https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed-update/user_uploads/low-priority-prescribing-consultation-guidance.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239946 question first answered 10/04/2019 13:28:54 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4056 label Biography information for Nic Dakin

1109126

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dermatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure patient experience is at the heart of commissioning for adult atopic dermatitis services in England.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	239948
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>The commissioning and configuration of dermatology services in England is a local matter. The majority of patients with dermatological disorders are managed in primary and community care and the local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way.</p><p> </p><p>The National Institute for Health and Care Excellence has published guidance on a number of dermatological conditions, including eczema, also known as atopic dermatitis, to support commissioners to plan and deliver services for local populations. ‘Atopic eczema in under 12’s: diagnosis and management’ includes recommendations that healthcare professionals should adopt a holistic approach at each consultation, taking into account severity of a condition and the impact this may have on quality of life.</p><p> </p><p>Healthcare professionals should be aware that all categories of severity of atopic eczema, even mild, can have a negative impact on psychological and psychosocial wellbeing and quality of life and that assessment of wellbeing should be carried out at every consultation. Furthermore, the guidance recommends using validated tools in the management of patients, such as Children's Dermatology Life Quality Index, Infants' Dermatitis Quality of Life Index or Dermatitis Family Impact questionnaire for quality of life. Where quality of life and psychosocial wellbeing has not improved despite treatment and improvement, patients should be referred for psychological advice. The guidance can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg57" target="_blank">www.nice.org.uk/guidance/cg57</a></p><p> </p><p>As set out in the NHS Long Term Plan, published on 7 January 2019, NHS England is taking action in range of areas to improve the care treatment and support provided to people with long term conditions. As part of this, it is continuing its expansion of Improving Access to Psychological Therapies (IAPT) services for adults with common mental health problems, with a focus on those with long-term conditions. IAPT services have now evolved to deliver benefits to people with long-term conditions, providing genuinely integrated care. By 2023/24, an additional 380,000 adults will be able to access IAPT services.</p><p> </p><p>No assessment has been made on the impact of atopic dermatitis on patient expenses, work days and mental health services. No meetings regarding atopic dermatitis have taken place in the last 12 months.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239949 239950 239951 question first answered 10/04/2019 13:36:32 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4056 label Biography information for Nic Dakin

1109127

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dermatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many meetings his Department has had with (a) patient and (b) professional atopic dermatitis groups in the last 12 months.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	239949
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>The commissioning and configuration of dermatology services in England is a local matter. The majority of patients with dermatological disorders are managed in primary and community care and the local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way.</p><p> </p><p>The National Institute for Health and Care Excellence has published guidance on a number of dermatological conditions, including eczema, also known as atopic dermatitis, to support commissioners to plan and deliver services for local populations. ‘Atopic eczema in under 12’s: diagnosis and management’ includes recommendations that healthcare professionals should adopt a holistic approach at each consultation, taking into account severity of a condition and the impact this may have on quality of life.</p><p> </p><p>Healthcare professionals should be aware that all categories of severity of atopic eczema, even mild, can have a negative impact on psychological and psychosocial wellbeing and quality of life and that assessment of wellbeing should be carried out at every consultation. Furthermore, the guidance recommends using validated tools in the management of patients, such as Children's Dermatology Life Quality Index, Infants' Dermatitis Quality of Life Index or Dermatitis Family Impact questionnaire for quality of life. Where quality of life and psychosocial wellbeing has not improved despite treatment and improvement, patients should be referred for psychological advice. The guidance can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg57" target="_blank">www.nice.org.uk/guidance/cg57</a></p><p> </p><p>As set out in the NHS Long Term Plan, published on 7 January 2019, NHS England is taking action in range of areas to improve the care treatment and support provided to people with long term conditions. As part of this, it is continuing its expansion of Improving Access to Psychological Therapies (IAPT) services for adults with common mental health problems, with a focus on those with long-term conditions. IAPT services have now evolved to deliver benefits to people with long-term conditions, providing genuinely integrated care. By 2023/24, an additional 380,000 adults will be able to access IAPT services.</p><p> </p><p>No assessment has been made on the impact of atopic dermatitis on patient expenses, work days and mental health services. No meetings regarding atopic dermatitis have taken place in the last 12 months.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239948 239950 239951 question first answered 10/04/2019 13:36:32 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4056 label Biography information for Nic Dakin

1109128

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dermatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to support the provision of psychodermatology services across England.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	239950
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>The commissioning and configuration of dermatology services in England is a local matter. The majority of patients with dermatological disorders are managed in primary and community care and the local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way.</p><p> </p><p>The National Institute for Health and Care Excellence has published guidance on a number of dermatological conditions, including eczema, also known as atopic dermatitis, to support commissioners to plan and deliver services for local populations. ‘Atopic eczema in under 12’s: diagnosis and management’ includes recommendations that healthcare professionals should adopt a holistic approach at each consultation, taking into account severity of a condition and the impact this may have on quality of life.</p><p> </p><p>Healthcare professionals should be aware that all categories of severity of atopic eczema, even mild, can have a negative impact on psychological and psychosocial wellbeing and quality of life and that assessment of wellbeing should be carried out at every consultation. Furthermore, the guidance recommends using validated tools in the management of patients, such as Children's Dermatology Life Quality Index, Infants' Dermatitis Quality of Life Index or Dermatitis Family Impact questionnaire for quality of life. Where quality of life and psychosocial wellbeing has not improved despite treatment and improvement, patients should be referred for psychological advice. The guidance can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg57" target="_blank">www.nice.org.uk/guidance/cg57</a></p><p> </p><p>As set out in the NHS Long Term Plan, published on 7 January 2019, NHS England is taking action in range of areas to improve the care treatment and support provided to people with long term conditions. As part of this, it is continuing its expansion of Improving Access to Psychological Therapies (IAPT) services for adults with common mental health problems, with a focus on those with long-term conditions. IAPT services have now evolved to deliver benefits to people with long-term conditions, providing genuinely integrated care. By 2023/24, an additional 380,000 adults will be able to access IAPT services.</p><p> </p><p>No assessment has been made on the impact of atopic dermatitis on patient expenses, work days and mental health services. No meetings regarding atopic dermatitis have taken place in the last 12 months.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239948 239949 239951 question first answered 10/04/2019 13:36:32 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4056 label Biography information for Nic Dakin